Synthetic Approaches to a Key Pyridone-carboxylic Acid Precursor Common to the HIV-1 Integrase Strand Transfer Inhibitors Dolutegravir, Bictegravir, and Cabotegravir
Overview
Authors
Affiliations
Dolutegravir (DTG), Bictegravir (BIC), and Cabotegravir (CAB) are the second-generation integrase strand transfer inhibitors (INSTIs) that have been FDA-approved for the treatment of HIV-1 infection. Preparation of these INSTIs utilizes the common intermediate 1-(2,2-dimethoxyethyl)-5-methoxy-6-(methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid (). Presented herein is a literature and patent review of synthetic routes used to access the pharmaceutically important intermediate . The review highlights the ways in which small fine-tuned synthetic modifications have been used to achieve good yields and regioselectivity of ester hydrolysis.
Mahajan P, Smith S, Li M, Craigie R, Hughes S, Zhao X ACS Infect Dis. 2024; 10(3):917-927.
PMID: 38346249 PMC: 10928719. DOI: 10.1021/acsinfecdis.3c00525.